Mike Wood on Muck Rack

Mike Wood

Verified
United Kingdom
As seen in: Pharmiweb.com, pharmiweb.jobs
Digital Marketing in Pharma, keen tech follower...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mike

Contact Mike, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Organon Announces MHRA Approval Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque to Five Years

|
By Mike Wood Verified
| Pharmiweb.com Verified
London, United Kingdom. – 21 May 2026 – Global women’s healthcare company, Organon, announced today that the UK’s Medical Healthcare products Regulatory Agency (MHRA) has approved an extension of the labelled duration of use for NEXPLANON® (etonogestrel). The contraceptive implant, indicated for prevention of pregnancy in women of reproductive potential, is now approved for up to five years, extending its previous three-year indication.
Open in Who Shared Issue with article?

Peer-Reviewed Studies Validate Linus Health AI as an Early Digital Biomarker for Alzheimer’s Pathology, Helping People Take Action Earlier to Slow Dis

|
By Mike Wood Verified
| Pharmiweb.com Verified
Findings show Linus Health’s AI can indicate Alzheimer’s pathology before noticeable symptoms—enabling earlier action to help protect independence and preserve what makes us who we are BOSTON, December 19, 2025 — AI can detect biological signs of Alzheimer’s disease years before symptoms are noted by the patient or their loved ones using only a 3-minute digital assessment delivered in a physician’s office.
Open in Who Shared Issue with article?

Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of C

|
By Mike Wood Verified
| Pharmiweb.com Verified
▪ Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets ▪ The agreement - OBT's second high-profile pharma collaboration this year - reflects the strong validation of OGAP®-Verify discovery platform's potential to drive oncology innovation ▪ OBT to receive an upfront payment and may be eligible to receive milestone payments, as well as royalties on net sales of products Oxford, UK and San Jose,...
Open in Who Shared View Duplicates (117) Issue with article?
See all 11 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified